January 29, 2016 1:32 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of
Gilead Sciences, Inc. (NASDAQ: GILD) lost more than 5 percent on Friday and hit a new 52-week low of $82.41 after the company
announced a change to its senior leadership.Effective March 10, 2016, Gilead's current Chairman and CEO John Martin will assume the role of Executive Chairman of the company. Replacing Martin will be John Milligan, the company's current President and Chief Operating Officer.Martin joined Gilead in 1990 and was named CEO in 1996 and Chairman of the Board in 2008. Milligan also joined the company in 1990 and was named Chief Operating Officer in 2007 and President in 2008.Investors and traders were also reacting to
Merck & Co., Inc. (NYSE: MRK)'s
announcement that the FDA approved its Hep C drug named ZEPATIER. According to Firece Biotech, Merck's new drug will compete "toe-to-toe" with Gilead's Hep C "goliath," Sovaldi.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.